Peroxisome proliferator-activated receptor-α selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice

Molecular and Cellular Biochemistry

Volumn 285, Issue 1-2, 2006, Pages 35-50

  Srivastava, Rai Ajit K ^a,e   Jahagirdar, Ravi ^a   Azhar, Salman ^b   Sharma, Somesh ^c   Bisgaier, Charles L ^d  

^a CloneGen Biotechnology   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Piramal Enterprises Limited   (India)

^d Esperion Therapeutics Inc   (United States)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

Atherosclerosis; Diabetes; Fenofibrate; LDL receptor knock out; Lipogenesis; Metabolic syndrome X; Obesity; PPAR; VCAM 1

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; APOLIPOPROTEIN C3; CHOLESTEROL; DIACYLGLYCEROL ACYLTRANSFERASE; FATTY ACID; FATTY ACID SYNTHASE; FENOFIBRATE; KETONE BODY; LIGAND; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); ROSIGLITAZONE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNCOUPLING PROTEIN 2; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CLINICAL FEATURE; CONTROLLED STUDY; DOWN REGULATION; ENERGY EXPENDITURE; ENZYME REGULATION; EPIDIDYMIS FAT; GENE CONTROL; HUMAN; HUMAN CELL; HYPOTHESIS; INSULIN SENSITIVITY; KETOGENESIS; LIPID STORAGE; MALE; MESENTERY; METABOLIC SYNDROME X; MOUSE; NONHUMAN; OBESITY; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION;

ADIPOSITY; ANIMALS; AORTA; CORONARY ARTERIOSCLEROSIS; DIET, ATHEROGENIC; ENERGY METABOLISM; GLUCONEOGENESIS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; INSULIN; INSULIN RESISTANCE; LEPTIN; LIGANDS; LIPID METABOLISM; LIPIDS; LIPOGENESIS; LIVER; MALE; METABOLIC SYNDROME X; MICE; MICE, INBRED C57BL; OBESITY; PPAR ALPHA; PROCETOFEN; RECEPTORS, LDL; TRIGLYCERIDES; WEIGHT GAIN;

ANIMALIA;

EID: 33646192257     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-005-9053-y     Document Type: Article

References (58)

1. Moller DE, Kaufman KD: Metabolic syndrome: A clinical and molecular perspective. Annual Review of Medicine 56: 45-62, 2005
2. Reaven GM: Pathophysiology of insulin resistance in human disease. Physiol Rev 75: 473-486, 1995
3. Srivastava RAK SrivaTtava N: Search for obesity drugs: targeting central and peripheral pathways. Curr Med Chem- Immunol, Endo & Met Ag 4: 75-90, 2004
4. Szapary PO, Rader DJ: The triglyceride-higA-density lipoprotein axis: an important target of therapy? Am Heart J 148: 211-221, 2004
5. Sowers JR, Epstein M, Frohlich ED: Diabetes, hypertension, and cardiovascular disease: An update. Hypertension 37: 1053-1059, 2001
6. Norhammar A, Malmberg K, Diderholm E, Lagerqvist B, Lindahl B, Ryden L, Wallentin L: Tiabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization. J Am Coll Cardiol 43(4): 585-591, 2004
7. Candido R, SrAvastava P, Cooper ME, Burrell LM: Diabetes mellitus: a cardiovascular disease. Curr Opin Investig Drugs 4: 1088-1094, 2003
8. Rubins HB: Triglycerides and coronarI heart disease: implications of recent clinical trials. J Cardiovasc Risk 7: 339-345, 2000 (Review)
9. George Steiner and Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357: 905-910, 2001
10. Krentz AJ: Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab Suppl 1: S19-27, 2003
11. Reaven G, Abbasi F, McLaughlin T: Obesity, insulin resistance, and cardiovascular disease. Recent Prog Horm Res 59: 207-223, 2004 (Review)
12. Kotani K, Peroni OD, Minokoshi Y, Boss O, Kahn BB: GLUT4 glucose transporter deficiency increases hepatic lipid production and peripheral lipid utilization. J Clin Invest 114: 1666-1675, 2004
13. Adeli K, Taghibiglou C, Van Iderstine SC, Lewis GF: Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. Trends Cardiovasc Med 11: 170-176, 2001 (Review)
14. Taghibiglou C, Carpentier A, Van Iderstine SC, Chen B, Rudy D, Aiton A, Lewis GF, Adeli K: Mechanisms of hepatic very low density lipoprotein overproduction in insulin resistance. Evidence for enhanced lipoprotein assembly, reduced intracellular ApoB degradation, and increased microsomal triglyceride transfer protein in a fructose-fed hamster model. J Biol Chem 275: 8416-8425, 2000
15. Fazio S, Linton MF: The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr Atheroscler Rep 6: 148-157, 2004 (Review)
16. Duez H, Lefebvre B, Poulain P, Pineda Torra I, Percevault F, Luc G, Peters JM, Gonzalez FJ, Gineste R, Helleboid S, Fruchart JC, Fievet C, Lefebvre P, Staels B: Regulation of human ApoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor{alpha}modulation. Arterioscler Thromb Vasc Biol 225: 585-591, 2004
17. Huang B, Wu P, Bowker-Kinley MM, Harris RA: Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferator-activated receptor-alpha ligands, glucocorticoids, and insulin. Diabetes 51: 276-283, 2002
18. Frederiksen KS, Wulff EM, Sauerberg P, Mogensen JP, Jeppesen L, Fleckner J: Prediction of PPAR-alpha ligand-mediated physiological changes using gene expression profiles. J Lipid Res 45: 592-601, 2004
19. Son C, Hosoda K, Matsuda J, Fujikura J, Yonemitsu S, Iwakura H, Masuzaki H, Ogawa Y, Hayashi T, Itoh H, Nishimura H, Inoue G, Yoshimasa Y, Yamori Y, Nakao K: Up-regulation of uncoupling protein 3 gene expression by fatty acids and agonists for PPARs in L6 myotubes. Endocrinology 142: 4189-4194, 2001
20. Frederiksen KS, Wulff EM, Sauerberg P, Mogensen JP, Jeppesen L, Fleckner J: Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis. Diabetes 52: 2249-2259, 2003
21. Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B: Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275: 16638-16642, 2000
22. Guerre-Millo M, Rouault C, Poulain P, Andre J, Poitout V, Peters JM, Gonzalez FJ, Fruchart JC, Reach G, Staels B: PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance. Diabetes 50: 2809-2814, 2001
23. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK: Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106: 523-531, 2000
24. Jeong S, Kim M, Han M, Lee H, Ahn J, Kim M, Song YH, Shin C, Nam KH, Kim TW, Oh GT, Yoon M: Fenofibrate prevents obesity and hypertriglyceridemia in low-density lipoprotein receptor-null mice. Metabolism 53: 607-613, 2004
25. Aalto-Setala K, Fisher EA, Chen X, Chajek-Shaul T, Hayek T, Zechner R, Walsh A, Ramakrishnan R, Ginsberg HN, Breslow JL: Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest 90(5): 1889-1900, 1992
26. Haubenwallner S, Essenburg AD, Barnett BC, Pape ME, DeMattos RB, Krause BR, Minton LL, Auerbach BJ, Newton RS, Leff T, et al.: Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: A potential physiologic basis for their mode of action. J Lipid Res 36: 2541-2551, 1995
27. Frenkel B, Bishara-Shieban J, Bar-Tana J: The effect of beta,beta′-tetramethylhexadecane-dioic acid (MEDICA 16) on plasma very-low-density lipoprotein metabolism in rats: Role of apolipoprotein C-III. Biochem J 298: 409-414, 1994
28. Bisgaier CL, Essenburg AD, Barnett BC, Auerbach BJ, Haubenwallner S, Leff T, White AD, Creger P, Pape ME, Rea TJ, Newton RS: A novel compound that elevates high density lipoprotein and activates the peroxisome proliferator activated receptor. J Lipid Res 39: 17-30, 1998. Erratum in: J Lipid Res 39: 1317, 1998
29. Srivastava RAK, Jiao S, Tang J, Pfleger B, Kitchens T, Schonfeld G: In vivo regulation of LDL receptor and apoB gene expressions in inbred strains of mice by dietary fatty acids and cholesterol. Biochim Biophys Acta 1086: 29-43, 1991
30. Srivastava RAK, Tang J, Krul ES, Pfleger B, Kitchens RT, Schonfeld G: Dietary fatty acids and cholesterol differ in their effects on the in vivo regulation of apoAI and apoAII gene expressions in inbred strains of mice. Biochim Biophys Acta 1125: 251-261, 1992
31. Ojeda MO, van't Veer C, Fernandez Ortega CB, Arana Rosainz Mde J, Buurman WA: Inflamm Res 54: 74-81, 2005
32. Srivastava RAK, Toth L, Srivastava N, Maeda N, Schonfeld G: Regulation of the apolipoprotein B in heterozygous hypobetalipoproteinemic knock-out mice expressing truncated apoB, B81. Low production and enhanced clearance of apoB cause low levels of apoB. Mol Cell Biochem 202: 37-46, 1999
33. Srivastava RAK: Analysis of RNA by Northern blotting using riboprobes. Methods in Molecular Biology 86: 103-112, 1998
34. Srivastava RAK, Srivastava N, Maurizio A, Lin RC, Korach K, Lubahn D, Schonfeld G: Regulation of apolipoprotein E gene expression by estrogen occurs by translational mechanism via estrogen receptor mediated pathway. J Biol Chem 272: 33360-33366, 1997
35. Zhang WJ, Frei B: Albumin selectively inhibits TNF alpha-induced expression of vascular cell adhesion molecule-1 in human aortic endothelial cells. Cardiovasc Res 55: 820-829, 2002
36. Kramer D, Shapiro R, Adler A, Bush E, Rondinone CM: Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats. Metabolism 200150: 1294-1300, 2001
37. Werner AL: Travaglini MTA review of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy 21: 1082-99, 2001 (Review)
38. Miyake JH, Wang SL, Davis RA: Bile acid induction of cytokine expression by macrophages correlates with repression of hepatic cholesterol 7alpha-hydroxylase, J Biol Chem 275: 21805-21808, 2000
39. Choi JS, Choi YJ, Park SH, Kang JS, Kang YH: Flavones mitigate tumor necrosis factor-alpha-induced adhesion molecule upregulation in cultured human endothelial cells: Role of nuclear factor-kappa B. J Nutr 134: 1013-1019, 2004
40. Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD: A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 296: 1703-1706, 2002
41. Schreyer SA, Vick C, Lystig TC, Mystkowski P, LeBoeuf RC: LDL receptor but not apolipoprotein E deficiency increases diet-induced obesity and diabetes in mice. Am J Physiol 282: E207-E214, 2002
42. Schreyer SA, Lystig TC, Vick CM, LeBoeuf RC: Mice deficient in apolipoprotein E but not LDL receptors are resistant to accelerated atherosclerosis associated with obesity. Atherosclerosis 171: 49-55, 2003
43. Duez H, Chao YS, Hernandez M, Torpier G, Poulain P, Mundt S, Mallat Z, Teissier E, Burton CA, Tedgui A, Fruchart JC, Fievet C, Wright SD, Staels B: Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem 277: 48051-48057, 2002
44. Mancini FP, Lanni A, Sabatino L, Moreno M, Giannino A, Contaldo F, Colantuoni V, Goglia F: Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats. FEBS Lett 491: 154-158, 2001
45. Schwartz S, Raskin P, Fonseca V, Graveline JF: Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. (1998) N Eng J Med 338: 861-866, 1998
46. Linden D, Lindberg K, Oscarsson J, Claesson C, Asp L, Li L, Gustafsson M, Boren J, Olofsson SO: Influence of peroxisome proliferator-activated receptor alpha agonists on the intracellular turnover and secretion of apolipoprotein (Apo) B-100 and ApoB-48. J Biol Chem 277: 23044-23053, 202, 2002
47. Frederiksen KS, Wulf EM, Wassermann K, Sauerberg P, Fleckner J: Identification of hepatic transcriptional changes in insulin-resistant rats treated with peroxisome proliferator activated receptor-alpha agonists. J Mol Endocrinol 30: 317-329, 2003
48. Goudriaan JR, Espirito Santo SM, Voshol PJ, Teusink B, van Dijk KW, van Vlijmen BJ, Romijn JA, Havekes LM, Rensen PC: The VLDL receptor plays a major role in chylomicron metabolism by enhancing LPL-mediated triglyceride hydrolysis. J Lipid Res 45: 1475-1481, 2004
49. Cases S, Stone SJ, Zhou P, Yen E, Tow B, Lardizabal KD, Voelker T, Farese RV, Jr: Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. J Biol Chem 276: 38870-38876, 2001
50. Goodpaster BH, Kelley DE: Role of muscle in triglyceride metabolism. Curr Opin Lipidol 9: 231-236, 1998
51. Ye JM, Doyle PJ, Iglesias MA, Watson DG, Cooney GJ, Kraegen EW: Peroxisome proliferator-activated receptor (PPAR)-alpha activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats: Comparison with PPAR-gamma activation. Diabetes 50: 411-417, 2001
52. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 95: 2409-2415, 1995
53. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance. Science 59: 87-91, 1993
54. Staels B, Koenig W, Habib A, Merval R, Lebret M, Pineda Torra I, Delerive P, Fadel A, Chinetti G, Fruchart J -C, Najib J, Maclouf J, Tedgui A: Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393: 790-793, 1998
55. Fu T, Kashireddy P, Borensztajn J: The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E. Biochem J 373: 941-947, 2003
56. Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK: Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest 114: 1564-1576, 2004
57. Branen L, Havgaard L, Nitulescu M, Bengtsson E, Nilsson J, Jovinge S: Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscl Thromb Vasc Biol 24: 2137-2142, 2004
58. Cybulsky MI, Iiyama K, Li H, Zhu S, Chen M, IIyama M, Davis V, Gutrerrez-Ramos J, Connelly PW, Milstone DS: A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 107: 1255-1262, 2001